Brief: U.S. FDA Approves Update To The Label For Winrevair To Include Data From The Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed With Pulmonary Arterial Hypertension
22/09/2026 11:48
BRIEF-U.S. FDA Approves Update To The Label For Winrevair To Include Data From The Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed With Pulmonary Arterial Hypertension Sept 22 (Reuters) - Merck & Co Inc MRK.N:
U.S. FDA APPROVES UPDATE TO THE LABEL FOR WINREVAIR™ (SOTATERCEPT-CSRK) TO INCLUDE DATA FROM THE PHASE 3 HYPERION TRIAL EVALUATING ADULTS RECENTLY DIAGNOSED WITH PULMONARY ARTERIAL HYPERTENSION (PAH, WHO* GROUP 1 PULMONARY HYPERTENSION)
Source text: ID:nBwbRpBWGa
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Merck & Co
See all newsBrief: European Commission Approves Keytruda Plus Padcev As Perioperative Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
US STOCKS-Dow leads Wall Street higher, investors focus on healthcare stocks
Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Live Markets: Dot-com deja vu? Why Goldman Sachs is calling time on the momentum trade
Factbox: Pharma sector doubles down on AI to slash costs, timelines